6K9.F - Context Therapeutics Inc.
| Previous Close | 0.8050 |
| Open | 0.9700 |
| Bid | 1.1400 x N/A |
| Ask | 1.1900 x N/A |
| Day's Range | 0.9700 - 0.9700 |
| 52 Week Range | 0.4200 - 2.1960 |
| Volume | |
| Avg. Volume | 167 |
| Market Cap | 17.058M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1500 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Simply Wall St.Will Context Therapeutics (NASDAQ:CNTX) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
GlobeNewswireContext Therapeutics Reports First Quarter 2023 Operating and Financial Results
CTIM-76 IND filing on track for Q1 2024 Preclinical data on CLDN6 bispecific antibody CTIM-76 presented at AACR Annual Meeting 2023 Cash and cash equivalents of $29.8 million as of March 31, 2023 PHILADELPHIA, May 10, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company dedicated to improving the lives of patients living with cancer, today announced its financial results for the first quarter ended March 31, 2023, and reporte
News DirectContext Therapeutics CTIM-76 bispecific antibody preclinical data presented at AACR Annual Meeting
Context Therapeutics CEO Marty Lehr joins Proactive's Natalie Stoberman to discuss CTIM-76 preclinical data presented at the American Association for Cancer Research (AACR) Annual Meeting 2023.
ACCESSWIRESignificant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A Difference
Context Therapeutics Inc. (NASDAQ:CNTX) is a biopharmaceutical company committed to advancing medicines for solid tumors by harnessing novel and innovative treatment targets such as Claudin 6 (CLDN6).
- GlobeNewswire
Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on April 5, 2023
Presenting Companies to Host 25 Minute Presentations Followed by Question-and-Answer Session; Conference Open to all Retail and Institutional InvestorsNEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will host its Spotlight Emerging Growth Invitational Investor Conference on April 5, 2023. The conference, which is open to all retail and institutional investors, will consist of a series of twenty-five-min
- GlobeNewswire
Context Therapeutics to Participate in Two April 2023 Investor Conferences
PHILADELPHIA, April 03, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company developing novel treatments for solid tumors, today announced that Chief Executive Officer Martin Lehr will participate virtually in two investor conferences in April 2023. Details of the events are as follows: Diamond Equity Emerging Growth Invitational Investor Conference: The Company will present on Wednesday, April 5 at 9:40 a.m. ET. To register
- GlobeNewswire
Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates
Company prioritizing pipeline to focus on CTIM-76 development and discontinuing ONA-XR program Cash runway extended into late 2024 CTIM-76 preclinical data to be presented at AACR Annual Meeting 2023 PHILADELPHIA, March 22, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company developing novel treatments for solid tumors, today announced financial results for the year ended December 31, 2022. Additionally, the Company announce
- GlobeNewswire
Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
Context to host webinar with AACR presenter on Monday, April 17, 2023, at 4:30 p.m. ETPHILADELPHIA, March 15, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company developing novel treatments for solid tumors, with a primary focus on female cancers, today announced that an abstract regarding Context’s preclinical candidate, CTIM-76, a Claudin 6 x CD3 bispecific antibody, has been selected for poster presentation
- GlobeNewswire
UPDATE -- Diamond Equity Research Initiates Coverage on Context Therapeutics Inc. (NASDAQ: CNTX)
NEW YORK, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of Context Therapeutics Inc. (NASDAQ: CNTX). The in-depth 26-page initiation report includes detailed information on the Context Therapeutics’ business model, services, industry, valuation, management, and risks. The full research report is available here. Highlights from the report include: Promising Pipeline of Novel Sy
News DirectContext Therapeutics announces positive responses in Phase 2 OATH clinical trial
Context Therapeutics CEO Marty Lehr joined Proactive's Natalie Stoberman to announce two clinical responses from its Phase 2 OATH Clinical Trial.
- GlobeNewswire
Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
ONA-XR initial data signals positive clinical activity and confirmed tumor shrinkage ONA-XR continues to be safe and well-tolerated PHILADELPHIA, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a company developing novel treatments for solid tumors, with a primary focus on female cancers, today announced that two patients have achieved a confirmed partial response (PR) among the first 12 patients (9 evaluable) enrolled in the Phase 2 OATH
- GlobeNewswire
Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer
First endocrine innovation in more than 20 years which has shown improved efficacy over standard-of-care treatments in patients with advanced breast cancer ORSERDU is being evaluated in combination with Context’s ONA-XR in the ongoing ELONA trial PHILADELPHIA, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a company developing novel treatments for solid tumors, with a primary focus on female cancers, today announced that its clinical tria
- GlobeNewswire
Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
Lonza to support the development and manufacturing of CTIM-76, Context’s CLDN6 x CD3 bispecific antibody clinical candidate The bispecific antibody-based therapy is being developed to redirect T-cell mediated lysis toward malignant cells expressing CLDN6 PHILADELPHIA and BASEL, Switzerland, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing medicines for solid tumors, and Lonza, a global de
- GlobeNewswire
Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones
CTIM-76 nominated as Claudin 6 x CD3 bispecific antibody clinical candidate Encouraging endometrial and breast cancer data in ongoing ONA-XR Phase 2 trials, with additional data updates expected in 2023 ELONA breast cancer trial open and enrolled first patient PHILADELPHIA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company developing novel treatments for solid tumors, with a primary focus on female
- GlobeNewswire
Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer
Data presented at San Antonio Breast Cancer Symposium® demonstrate preliminary 4-month PFS rate of 44% in ongoing Phase 2 trial in second- or third-line metastatic breast cancer PFS follows recently disclosed positive preliminary data in ongoing Phase 2 endometrial cancer trial PHILADELPHIA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, announced p
- GlobeNewswire
Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors
CTIM-76 named as lead candidate to target Claudin 6 positive cancers IND submission expected in Q1 2024 Context to host webinar on Thursday, December 1, 2022, at 11 a.m. ET PHILADELPHIA, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, today announced the selection of CTIM-76, a T cell-engaging bispecific antibody, as its lead clinical development can
- Simply Wall St.
Is Context Therapeutics (NASDAQ:CNTX) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- GlobeNewswire
Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium
Company reports initial ONA-XR data from the ongoing Phase 2 SMILE trial for metastatic breast cancer will be presentedPHILADELPHIA, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, today announced clinical data on onapristone extended release (ONA-XR) will be presented at the 2022 San Antonio Breast Cancer Symposium® (SABCS®) taking place in San Anto
- GlobeNewswire
Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results
Company reports preliminary ONA-XR data from two ongoing Phase 2 trials ONA-XR demonstrates preliminary 4-month PFS rate of 77.7% in ongoing Phase 2 trial evaluating the combination of ONA-XR and the antiestrogen anastrozole in PR+ recurrent endometrial cancer ONA-XR continues to exhibit favorable safety and tolerability profile Cash and cash equivalents of $39 million as of September 30, 2022, expected to provide runway into Q1 2024 PHILADELPHIA, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Context Therap
- Newsfile
Context Therapeutics to Participate in the ThinkEquity Conference
Philadelphia, Pennsylvania--(Newsfile Corp. - October 20, 2022) - Context Therapeutics Inc. (NASDAQ: CNTX) ("Context" or the "Company"), a women's oncology company developing novel treatments for breast and gynecologic cancers, today announced the Company will participate in The ThinkEquity Conference, taking place on October 26, 2022, at The Mandarin Oriental Hotel in New York City.Context CEO Martin Lehr will present at 9:30 a.m. ET on October 26. Interested parties can register to attend here
- GlobeNewswire
Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024
Company to focus resources on advancing ONA-XR ELONA Phase 1b/2 clinical trial and on advancing CLDN6xCD3 bispecific antibody toward INDPHILADELPHIA, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecological cancers, today announced updated cash guidance to extend its runway into Q1 2024. The company plans to defer noncritical R&D activities, reduce future overhead
- Simply Wall St.
A number of insiders bought Context Therapeutics Inc. (NASDAQ:CNTX) stock last year, which is great news for shareholders
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
- GlobeNewswire
Context Therapeutics® to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
PHILADELPHIA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecological cancers, today announced that Chief Executive Officer Martin Lehr will participate in a fireside chat during the H.C. Wainwright 24th Annual Global Investment Conference taking place virtually and in-person September 12-14, 2022, in New York City. The fireside chat will be available on demand fo
- GlobeNewswire
Context Therapeutics® Reports Second Quarter 2022 Operating and Financial Results
Announced new clinical trial collaboration with Menarini Group to evaluate ONA-XR plus elacestrant in metastatic breast cancer Results of the monotherapy portion of Phase 2 ONA-XR clinical trial in granulosa cell tumors of the ovary presented at the 2022 ASCO Annual Meeting Preliminary results from multiple clinical trials planned for Q4 2022 On track for development candidate selection of CLDN6xCD3 bispecific in Q4 2022 PHILADELPHIA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (
CNW GroupContext Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination
Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a women's oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, and The Menarini Group ("Menarini") today announced a clinical trial collaboration and supply agreement for Menarini's oral selective estrogen receptor degrader (SERD), elacestrant.